老百姓大藥房股份有限公司盈利能力分析[摘要]隨著醫(yī)療體制改革的進(jìn)一步推進(jìn)，人們更加關(guān)注自己和家人的身體健康，行業(yè)發(fā)展進(jìn)程不斷加速，醫(yī)藥領(lǐng)域的市場競爭已呈現(xiàn)出白熱化的態(tài)勢。本文以老百姓大藥房股份有限公司（以下簡稱老百姓大藥房）為例，對公司的盈利能力進(jìn)行深入分析，對醫(yī)藥行業(yè)公司的盈利能力進(jìn)行深入分析。本文綜合運用財務(wù)比率分析、趨勢分析及同行業(yè)對比分析等方法，對公司近五年財務(wù)數(shù)據(jù)展開深入刨析。通過凈資產(chǎn)收益率、銷售凈利率等核心指標(biāo)，系統(tǒng)探究企業(yè)盈利能力現(xiàn)狀、演變趨勢及影響因素，力求全面揭示企業(yè)財務(wù)運營特征與發(fā)展態(tài)勢。同時對公司面臨的市場競爭、政策變化、成本上升、電商沖擊、供應(yīng)鏈不穩(wěn)定、數(shù)字化轉(zhuǎn)型投入等問題進(jìn)行分析以及針對以上問題提出相應(yīng)的改進(jìn)措施，旨在助力老百姓大藥房進(jìn)一步提升盈利能力，為整個醫(yī)藥行業(yè)的發(fā)展提供參考和借鑒。[關(guān)鍵詞]老百姓大藥房；盈利能力；財務(wù)分析；醫(yī)藥行業(yè)

Abstract:Withthefurtheradvancementofthemedicalsystemreform,peoplepaymoreattentiontotheirownandtheirfamily'shealth,andthedevelopmentprocessoftheindustryisaccelerating.Themarketcompetitioninthepharmaceuticalfieldhasshownawhite-hottrend.ThisarticletakesthePeople'sPharmacyCo.,Ltd.(hereinafterreferredtoasPeople'sPharmacy)asanexampletoconductanin-depthanalysisofthecompany'sprofitabilityandtheprofitabilityofpharmaceuticalcompanies.Thisarticlecomprehensivelyusesfinancialratioanalysis,trendanalysis,andcomparativeanalysiswithpeerstoconductin-depthanalysisofthecompany'sfinancialdataoverthepastfiveyears.Throughcoreindicatorssuchasreturnonnetassetsandnetprofitmarginonsales,thesystemsystematicallyexploresthecurrentstate,evolutiontrend,andinfluencingfactorsofcorporateprofitability,strivingtocomprehensivelyrevealthecharacteristicsanddevelopmenttrendofcorporatefinancialoperations.Atthesametime,itanalyzesthemarketcompetition,policychanges,risingcosts,e-commerceimpact,unstablesupplychain,digitaltransformationinvestmentandotherissuesfacedbythecompany,andproposescorrespondingimprovementmeasurestoaddresstheseissues.TheaimistohelpthePeople'sPharmacyfurtherimproveitsprofitabilityandprovidereferenceforthedevelopmentoftheentirepharmaceuticalindustry.Keywords:People'sPharmacy;Profitability;FinancialAnalysis;PharmaceuticalIndustry目錄TOC\o"1-3"\h\u224221緒論 -2024年老百姓大藥房合并利潤表（續(xù)）單位：人民幣元報告期2024年2023年2022年2021年2020年六、凈利潤6.851億11.24億9.762億7.867億7.645億(一)按經(jīng)營持續(xù)性分類持續(xù)經(jīng)營凈利潤6.851億11.24億9.762億7.867億7.645億(二)按所有權(quán)歸屬分類歸屬于母公司股東的凈利潤5.191億9.290億7.850億6.692億6.211億少數(shù)股東損益1.661億1.945億1.913億1.175億1.434億扣除非經(jīng)常性損益后的凈利潤4.963億8.438億7.357億5.725億5.450億七、每股收益基本每股收益0.68001.23001.36001.23001.5400稀釋每股收益0.68001.23001.36001.23001.5200八、其他綜合收益224.9萬-3364萬8421萬--歸屬于母公司股東的其他綜合收益224.9萬-3364萬8421萬--九、